ADC Antibody

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.

Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators (Datopotamab deruxtecan).

Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).

Polatuzumab is a monoclonal antibody that targets CD79b and carries chemotherapeutically active molecules.Polatuzumab adheres to CD79b proteins and transports the chemotherapeutically active molecules into cells to kill them.Polatuzumab can be used to synthesize the antibody-compound coupling, Polatuzumab Vedotin.

Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17). Belantamab is a naked antibody to Belantamab mafodotin and can be used to synthesize antibody-active molecule conjugates (Belantamab mafodotin).

Disitamab Vedotin (RC48-0) is a humanized monoclonal antibody that targets HER2 and can be utilized in creating antibody-drug conjugates (ADCs), specifically referred to as Disitamab Vedotin [1].

Naratuximab (Anti-TSPAN26 CD37 Reference Antibody) is a humanized monoclonal antibody against CD37 that can be used to synthesize the ADC compound Naratuximab emtansine.

Lonigutamab (hz208F2-4) is a humanized monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) for the study of thyroid eye disease.

Iladatuzumab (MCDS0593A), a humanized IgG1 monoclonal antibody targeting CD79B, serves as a precursor for the synthesis of antibody-drug conjugates (ADCs), such as Iladatuzumab vedotin (DCDS0780A), with potential applications in B-cell non-Hodgkin lymphoma (B-NHL) research [1] [2].

Lorvotuzumab (Anti-NCAM1 CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.

Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to synthesize Gemtuzumab ozogamicin, an antibody coupled compound (ADC) Gemtuzumab is used in the study of acute myeloid leukemia.

Denintuzumab (hBU 12), a recombinant humanized anti-CD19 monoclonal antibody, serves as the antibody component in the synthesis of antibody-drug conjugates (ADC), notably Denintuzumab Mafodotin (SGN-CD19A). This ADC is utilized in the research of acute lymphoblastic leukemia [1].

Moxetumomab, a recombinant immunotoxin targeting CD22, is utilized in the study of hairy cell leukemia (HCL) [1] [2].

Vobramitamab, a humanized B7-H3 monoclonal antibody (mAb), is conjugated to the prodrug seco-DUBA through a cleavable linker, creating the antibody-drug conjugate (ADC) known as MGC018 [1].

Izeltabart (IMGC-936) is a Maytansinoid-based Antibody-Drug Conjugate (ADC) that specifically targets ADAM9. It consists of a high-affinity humanized antibody conjugated site-specifically to DM21-C, a linker-payload that combines a microtubule-disrupting Maytansinoid with a stable tripeptide linker, maintaining a drug-to-antibody ratio of approximately 2.0. Izeltabart demonstrates cytotoxicity against ADAM9-expressing human tumor cell lines and possesses significant antitumor efficacy in xenograft tumor models [1].

Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3 for research in acute myeloid leukemia.

Lupartumab (BAY 1112623) is a monoclonal antibody targeting LYPD3 (C4.4A) and is employed in the synthesis of antibody-active molecular couplers for studying LYPD3-associated tumor diseases.

Ozuriftamab, a naked (human IgG1 kappa) antibody targeting the (receptor tyrosine kinase-like orphan receptor 2 (ROR2)), serves as a precursor for the synthesis of antibody-drug conjugates (ADCs) [1].

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targeting tissue factor (TF), utilized in antibody-conjugating drugs for cancer research.

Briobacept (BR 3FC), a selective human monoclonal antibody, targets BLyS (BAFF) to induce B-cell apoptosis and is a recombinant glycoprotein comprising two BLyS receptor (BR3) molecules fused to the Fc domain of human IgG1. It has applications in the study of rheumatoid arthritis (RA) [1] [2].

Cantuzumab, a monoclonal antibody, binds to the CanAg antigen and is commonly conjugated with various cytotoxic agents to form antibody-drug conjugates (ADCs), including Cantuzumab mertansine and Cantuzumab ravtansine [1].

Praluzatamab is a monoclonal antibody targeting an activated white blood cell adhesion molecule (ALCAM CD116). It is a naked antibody used to synthesize antibody active molecule conjugates (Praluzatamab ravtansine) and can be employed to study breast cancer.

Azintuxizumab, an IgG4 bispecific antibody, specifically targets the B-cell maturation antigen (BCMA) and shows promise for the investigation of relapsed/refractory multiple myeloma (RRMM) [1].

Mipasetamab, an IgG1κ antibody, targets AXL, a tyrosine kinase receptor and TAM Receptor. It plays a crucial role in synthesizing ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC), known for its anti-tumor activity [1].

Mecbotamab vedotin (BA3011) is a humanized IgG1-κ antibody engineered to target the AXL receptor tyrosine kinase (AXL). Serving as a conditionally active biologic (CAB), mecbotamab is conjugated to monomethyl auristatin E (MMAE) through a cleavable linker, creating an antibody-drug conjugate (ADC) for therapeutic use [1] [2].

Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. This naked antibody can be used to synthesize antibody-active molecule conjugators [Inotuzumab ozogamicin] and to study acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

ABBV-303 is a multispecific NK cell antibody utilizing TriNKET technology to target c-Met for NK cell redirection therapy. It comprises three functional components: a single-chain variable fragment (scFV) targeting c-Met, a Fab arm engaging NKG2D, and an Fc fragment directed at NK cell CD16a [1].

Upifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study cancer.